Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Physiologic modeling of cyclosporin kinetics in rat and man


A physiologic pharmacokinetic model of cyclosporin has been developed in the rat aimed at predicting the time course of drug concentrations in blood, organs, and tissues. The model assumes that tissue distribution is perfusion-rate limited and that each tissue acts as a well-stirred compartment. The unbound equilibrium distribution ratios as well as the values of the fraction unbound and the distributon isotherm of cyclosporin between erythrocytes and plasma are included in the rate equations describing the time course of the drug concentration in each tissue. Parameter values for the rat were obtained experimentally from a continuous infusion study, in which 2.7 and I3.9mg/kg per day doses of cyclosporin were administered subcutaneously to each of two groups of rats by osmotic pumps for 6 days. Steady-state cyclosporin concentrations in blood, CSF, and 18 different organs and tissues, were determined by a monoclonal antibody RIA. Differences in values of the unbound equilibrium distribution ratios in some tissues and unbound clearance indicated that both the processes of distribution and elimination may have elements of nonlinearity over the range of dosing rales tested. The model was evaluated in the rat with a kinetic experiment in which a 6-mg/kg dose of cyclosporin was infused intravenously over 15 min, with measurements of blood concentrations until 56 hr. Good agreement was obtained for the volume of distribution at steady state (blood), V xs between the perfusion model and that calculated from the kinetic experiment. Also, the model prediction of the blood concentration temporal profile agreed closely with that observed except in the early moments, when distribution out of blood occurred considerably slower than predicted. On scaling the model up to humans, good agreement was found between the predicted plasma concentration-time profile and V ss ,and experimental data from the literature. Both rat and human data suggest that partition into adipose tissue plays an important role in the pharmacokinetics of cyclosporin.

This is a preview of subscription content, log in to check access.


  1. 1.

    J. F. Borel, C. Freurer, H. U. Gubler, and H. Staheiin. Biological effects of cyclosporin A: a new antilymphocytic agent.Agents Actions 6:468–475 (1976).

  2. 2.

    A. D. Hess and P. M. Colombani. Mechanism of action: In vitro studies. InCiclosporin. Progress in Allergy Vol. 38, S. Karger, Basel, 1986, pp. 198–221.

  3. 3.

    C. J. Green. Experimental transplantation. InCiclosporin. Progress in Allergy, Vol. 38, S. Karger, Basel, 1986, pp. 123–158.

  4. 4.

    T. Beveridge. Clinical transplantation—Overview. InCiclosporin. Progress in Allergy, Vol. 38, S. Karger, Basel, 1986, pp. 269–292.

  5. 5.

    R. B. Nussenblatt, H. C. Gunn, B. Ryffel, and J. F. Borel. Experimental autoimmunity. InCiclosporin. Progress in Allergy, Vol. 38, S. Karger, Basel, 1986, pp. 159–180.

  6. 6.

    B. V. Graffenried. Ciclosporin in autoimmune diseases. InCiclosporin. Progress in Allergy, Vol. 38, S. Karger, Basel, 1986, pp. 432–435.

  7. 7.

    S. K. Gupta, B. Legg, L. R. Solomon, R. W. G. Johnson, and M. Rowland. Pharmacokinetics of cyclosporin: Influence of rate of constant intravenous infusion in renal transplant patients.Br. J. Clin. Pharmacol. 24:519–526 (1987).

  8. 8.

    F. Follath, M. Wenk, S. Vozeh, G. Thiel, F. Brunner, R. Loertscher, M. Lemaire, K. Nussbaumer, W. Niederberger, and A. J. Wood. Intravenous cyclosporin kinetics in renal failure.Clin. Pharmacol. Ther. 34:638–643 (1983).

  9. 9.

    O. Wagner, E. Schreier, F. Heitz, and G. Maurer. Tissue distribution, disposition, and metabolism of cyclosporin in rats.Drug Metab. Dispos. 15:377–383 (1987).

  10. 10.

    K. Atkinson, J. Boland, K. Britton, and J. Biggs. Blood and tissue distribution of cyclosporin in humans and mice.Transpl. Proc. 15:2430–2449 (1983).

  11. 11.

    M. Ried, S. Gibbons, D. Kwok, C. T. Van Buren, S. Flechner, and B. D. Kahan. Cyclosporin levels in human tissues of patients treated for one week to one year.Transpl. Proc. 15:2434–2437 (1983).

  12. 12.

    G. Maurer, H. R. Loosly, E. Schreier, and B. Keller. Disposition of cyclosporin in several animal species and man. Structural elucidation of its metabolites.Drug Metab. Dispos. 12:120–126 (1984).

  13. 13.

    A. J. Wood, G. Maurer, W. Niederberger, and T. Beveridge. Cyclosporin: Pharmacokinetics, metabolism, and drug interactions.Transpl. Proc. 15:2409–2412 (1983).

  14. 14.

    P. E. Ball, H. Munzer, H. P. Keller, E. Abisch, and J. Rosenthaler, Specific [3H]radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in blood.Clin. Chem. 34:257–260 (1988).

  15. 15.

    B. Legg and M. Rowland. Cyclosporin A: Measurement of fraction unbound in plasma.J. Pharm. Pharmacol. 39:599–603 (1987).

  16. 16.

    D. H. Jung, H. G. Biggs, and W. R. Moorehead. Colorimetry of serum cholesterol with use of ferric acetate/uranyl acetate and ferrous sulfate/sulphuric acid reagents.Clin. Chem. 21:1526–1530 (1975).

  17. 17.

    M. Gibaldi and D. Perrier. (eds).Pharmacokinetics, 2nd ed., Marcel Dekker, New York, 1982.

  18. 18.

    K. S. Pang and M. Rowland. Hepatic clearance of drugs, I. Theoretical consideration of a “well stirred” and a “parallel tube” model. Influence of hepatic blood, plasma and blood binding and hepatocellular enzyme activity on hepatic drug clearance.J. Pharmacokin. Biopharm. 5:625–653 (1977).

  19. 19.

    W. Niederberger, M. Lemaire, G. Maurer, K. Nussbaumer, and O. Wagner. Distribution and binding of cyclosporin in blood and tissues.Transpl. Proc. 15:2419–2421 (1983).

  20. 20.

    B. Legg and M. Rowland. Cyclosporin: Erythrocyte binding and an examination of its use to estimate unbound concentration.Theor. Drug Monit. 10:16–19 (1988).

  21. 21.

    H. H. Donaldson.The rat. Data and Reference Tables, 2nd ed., Memoirs of the Wistar Institute of Anatomy and Biology, No. 6, Philadelphia, 1924, pp. 183–189.

  22. 22.

    Y. Igari, Y. Sugiyama, Y. Sawada, T. Iga, and M. Hanano. Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model.J. Pharmacokin. Biopharm. 11:577–593 (1983).

  23. 23.

    R. J. Lutz, R. L. Dedrick, H. B. Matthews, T. E. Eling, and M. W. Andersen. A preliminary pharmacokinetic model for several chlorinated biphenyls in the rat.Drug Metab. Dispos. 5:386–396 (1977).

  24. 24.

    J. Idvall, K. F. Aronsen, and P. Stenberg. Tissue perfusion and distribution of cardiac output during ketamine anaesthesia in normovolemic rats.Acta Anaesth. Scand. 24:257–263 (1980).

  25. 25.

    Y. Sasaki and H. N. Wagner Jr. Measurement of the distribution of cardiac output in unanesthetized rats.J. Appl. Physiol. 30:879–884 (1971).

  26. 26.

    A. Schoutens, P. Bergmann, and M. Verhas. Bone blood flow measured by85Sr microspheres and bone seeker clearances in the rat.Am. J. Physiol. 236:H1-H6 (1979).

  27. 27.

    H. J. Baker, (ed.).The Laboratory Rat Vol. I. In American College of Laboratory Animal Medicine Series, Academic Press, New York, 1979, p. 87.

  28. 28.

    J. P. Schaeffer. (ed.).Morris' Human Anatomy, 11th ed. Blakiston, London, 1953.

  29. 29.

    V. Fiserova-Bergerova. (ed.).Modelling of Inhalation Exposure to Vapors, Vol. I, CRC Press, Boca Raton, FL, 1983, p. 88.

  30. 30.

    A. C. Guyton. (ed.).Textbook of Medical Physiology, W. B. Saunders, Philadelphia, 1966, p. 279.

  31. 31.

    R. L. Dedrick, D. D. Forrester, and D. H. W. Ho. In vitro-in vivo correlation of drug metabolism. Deamination of 1-beta-D-arabinofuranosylcytosine.Biochem. Pharmacol. 21:1–16 (1972).

  32. 32.

    G. Bell, J. N. Davidson, and H. Scarborough, (ed.).Textbook of Physiology and Biochemistry, 6th ed., Livingstone, London, 1965, p. 512.

  33. 33.

    M. Rowland and T. N. Tozer. (eds.).Clinical Pharmacokinetics: Concepts and Applications, 2nd ed., Lea & Febiger, Philadelphia, 1989, chap. 19.

  34. 34.

    B. Legg, S. K. Gupta, and M. Rowland. A model to account for the variation in cyclosporin binding to plasma lipids in transplant patients.Ther. Drug Monit. 10:20–27 (1988).

  35. 35.

    R. J. Ptachcinski, R. Venkataramanan, and G. J. Burckart. Clinical pharmacokinetics of cyclosporin.Clin. Pharmacokin. 11:107–132 (1986).

  36. 36.

    J. K. Fazakorley and H. E. Webb. Cyclosporin, blood brain barrier, and multiple sclerosis.Lancet 2:889–890 (1985).

Download references

Author information

Correspondence to Malcolm Rowland.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bernareggi, A., Rowland, M. Physiologic modeling of cyclosporin kinetics in rat and man. Journal of Pharmacokinetics and Biopharmaceutics 19, 21–50 (1991). https://doi.org/10.1007/BF01062191

Download citation

Key words

  • cyclosporin
  • physiologic pharmacokinetic model
  • intravenous infusion
  • rat
  • man
  • osmotic pumps
  • distribution study
  • RIA
  • organs blood content
  • interspecies scaling